Lanreotide Acetate NDC 69097-880

NDC codes

FDA NDC Directory

Product NDC (as listed)69097-880Labeler and product segments. Claims need a package NDC.

Product NDC at billing width69097-0880Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
69097-880-67	69097088067	1 SYRINGE in 1 CARTON (69097-880-67) / .2 mL in 1 SYRINGEMarketed from Dec 24, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lanreotide Acetate
Generic name (nonproprietary): lanreotide acetate
Active ingredients: Lanreotide acetate — 60 mg/.2mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Cipla USA Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 215395
Marketing start: Dec 24, 2021
Listing expires: Dec 31, 2026
Other FDA classes: Somatostatin Receptor Agonists (Mechanism)
Identifiers: Product ID 69097-880_fd205110-15eb-4707-82b2-185e5bbf616bSPL ID fd205110-15eb-4707-82b2-185e5bbf616bSPL set ID 11da176a-99bc-4ada-8b3f-6bd2b37a6313RxCUI 749811, 749814, 749817UNII IEU56G3J9C
Pharmacologic class: Somatostatin Analog

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N469097088067 followed by a unit qualifier and the quantity

Package 69097-0880-67. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 1, 2024.

Indications (excerpt from the label)

Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 ) 1.1 Acromegaly Lanreotide Injection is indicated for the long-term treatment of acromegalic patients who have had an inadeq…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 215395

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 215395
Product	Strength	Form · route	Labeler	Product NDC
Lanreotide Acetate	Lanreotide acetate 120 mg/.5mL	InjectionSubcutaneous	Cipla USA Inc.	69097-870
Lanreotide Acetate	Lanreotide acetate 90 mg/.3mL	InjectionSubcutaneous	Cipla USA Inc.	69097-890